CN113966229A - 用于改善花生过敏患者的生活质量的方法 - Google Patents

用于改善花生过敏患者的生活质量的方法 Download PDF

Info

Publication number
CN113966229A
CN113966229A CN202080033786.0A CN202080033786A CN113966229A CN 113966229 A CN113966229 A CN 113966229A CN 202080033786 A CN202080033786 A CN 202080033786A CN 113966229 A CN113966229 A CN 113966229A
Authority
CN
China
Prior art keywords
patient
peanut
oral immunotherapy
administered
faqlq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080033786.0A
Other languages
English (en)
Chinese (zh)
Inventor
C·伯奇伍德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe des Produits Nestle SA
Original Assignee
Aimu Therapy Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aimu Therapy Co filed Critical Aimu Therapy Co
Publication of CN113966229A publication Critical patent/CN113966229A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
CN202080033786.0A 2019-05-10 2020-05-08 用于改善花生过敏患者的生活质量的方法 Pending CN113966229A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962846481P 2019-05-10 2019-05-10
US62/846,481 2019-05-10
US201962855384P 2019-05-31 2019-05-31
US62/855,384 2019-05-31
US202062967948P 2020-01-30 2020-01-30
US62/967,948 2020-01-30
PCT/US2020/032179 WO2020231843A1 (en) 2019-05-10 2020-05-08 Methods for improving the quality of life of a patient with a peanut allergy

Publications (1)

Publication Number Publication Date
CN113966229A true CN113966229A (zh) 2022-01-21

Family

ID=73289227

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080033786.0A Pending CN113966229A (zh) 2019-05-10 2020-05-08 用于改善花生过敏患者的生活质量的方法

Country Status (7)

Country Link
US (2) US11229673B2 (https=)
EP (1) EP3965815A4 (https=)
JP (1) JP7574222B2 (https=)
CN (1) CN113966229A (https=)
AU (1) AU2020276213A1 (https=)
CA (1) CA3137295A1 (https=)
WO (1) WO2020231843A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014159609A1 (en) 2013-03-14 2014-10-02 Allergen Research Corporation Peanut formulations and uses thereof
US12433945B2 (en) 2018-08-16 2025-10-07 Société des Produits Nestlé S.A. Peanut oral immunotherapy with maintenance dose
US12226448B2 (en) 2018-12-20 2025-02-18 Société des Produits Nestlé S.A. Peanut oral immunotherapy dosing schedule for missed doses
WO2022003604A1 (en) 2020-07-01 2022-01-06 Société des Produits Nestlé S. A. Determining medical staffing for oral immunotherapy
KR20230148769A (ko) 2022-04-15 2023-10-25 사회복지법인 삼성생명공익재단 경구면역요법을 이용한 식품알레르기 치료서비스 제공방법, 이를 구현하기 위한 기록매체에 저장된 컴퓨터 프로그램 및 시스템

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103596589A (zh) * 2011-03-17 2014-02-19 剑桥实业有限公司 花生过敏症的治疗
WO2019089978A1 (en) * 2017-11-02 2019-05-09 Aimmune Therapeutics, Inc. Methods of oral immunotherapy

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3809767A (en) 1969-05-12 1974-05-07 Griffith Laboratories Methods of making vegetable protein concentrates
AU1589492A (en) 1991-03-01 1992-10-06 Warner-Lambert Company Starch-based controlled release compositions
US20120164306A1 (en) 1993-08-03 2012-06-28 Girsh Leonard S Process for preparing hypoallergenic and reduced fat foods
JP3445593B2 (ja) 1994-09-10 2003-09-08 株式会社林原生物化学研究所 ペプチドとその用途
AU2065801A (en) 1999-12-06 2001-06-12 Panacea Pharmaceuticals, Llc Passive desensitization
AU1951001A (en) 2000-04-06 2001-09-17 Panacea Pharm Llc Microbial delivery system
WO2004047793A1 (en) 2002-11-26 2004-06-10 Alk-Abelló A/S Pharmaceutical allergen product
EP1599185A1 (en) 2003-02-28 2005-11-30 Alk-Abello A/S Dosage form having a saccharide matrix
EP1734975B1 (en) 2004-03-19 2015-06-10 Herbs Spring, LLC Herbal therapy for the treatment of food allergy
WO2005100995A2 (en) 2004-04-06 2005-10-27 Mount Sinai School Of Medicine Methods of determining allergen response using microarray imminoassay techinques
BRPI0520821A2 (pt) 2005-12-28 2009-06-30 Teva Pharma formulações farmacêuticas de fenofibrato com biodisponibilidade melhorada
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
HRP20200284T1 (hr) 2008-10-02 2020-07-10 Salix Pharmaceuticals, Ltd. Postupci liječenja hepatičke encefalopatije
BRPI0921507A2 (pt) 2008-11-19 2016-01-19 Avantor Performance Mat Inc composição, método de preparação de um excipiente, comprimido farmacêutico e método de preparação do mesmo
US8399519B2 (en) 2008-12-19 2013-03-19 Merz Pharma Gmbh & Co. Kgaa 1-amino-alkylcyclohexane derivatives for the treatment of mast cell mediated diseases
US8329208B2 (en) 2009-07-28 2012-12-11 Methylation Sciences International Srl Pharmacokinetics of S-adenosylmethionine formulations
EP2364690A1 (en) 2010-02-12 2011-09-14 Centro De Ingenieria Genetica Y Biotecnologia Orally administrable pharmaceutical pellet of epidermal growth factor
JP5800527B2 (ja) 2010-03-30 2015-10-28 日東電工株式会社 安定化医薬組成物、安定化医薬組成物溶液製剤、フィルム状製剤及びフィルム状製剤の製造方法
AR081776A1 (es) 2010-06-30 2012-10-17 Novartis Ag Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, proceso para la produccion de la composicion
US20140207105A1 (en) 2011-08-31 2014-07-24 Perosphere, Inc. Methods for Effectively and Rapidly Desensitizing Allergic Patients
WO2013087119A1 (en) 2011-12-16 2013-06-20 Hal Allergy Holding B.V. Pharmaceutical formulations and the use thereof for the treatment of peanut allergy
CN104080465A (zh) 2012-01-13 2014-10-01 科.汉森有限公司 用于预防或治疗上呼吸道感染的鼠李糖乳杆菌和动物双歧杆菌乳亚种
CN109125283A (zh) 2013-03-14 2019-01-04 艾慕恩治疗公司 用于口服脱敏的花生制剂的制备
WO2014159609A1 (en) 2013-03-14 2014-10-02 Allergen Research Corporation Peanut formulations and uses thereof
KR102233251B1 (ko) 2013-04-03 2021-03-26 엔-폴드 엘엘씨 신규 나노입자 조성물
US9456628B2 (en) 2013-06-13 2016-10-04 D&E Gillespie Enterpries LLC Methods and products to provide oral nutritional care to subjects with dementia
US20150343075A1 (en) 2014-06-02 2015-12-03 Aimmune Therapeutics Placebo formulations and uses thereof
EP3185900A4 (en) 2014-08-25 2018-05-02 Aimmune Therapeutics, Inc. Egg protein formulations and methods of manufacture thereof
GEAP201814459A (en) 2014-09-04 2018-09-10 Helsinn Healthcare Sa Medical treatments based on anamorelin
UA122670C2 (uk) 2014-09-08 2020-12-28 Сефалон, Інк. Спосіб лікування еозинофільної астми у пацієнта
JP2020514306A (ja) 2017-01-13 2020-05-21 アイミューン セラピューティクス，インコーポレイテッド 経口免疫療法用のナッツ粉および製剤の製造方法
FR3062797B1 (fr) * 2017-02-10 2025-03-07 Centre Hospitalier Et Univ De Clermont Ferrand Gelule a liberation gastro-intestinale destinee a etre utilisee dans une methode permettant de desensibiliser et/ou d'induire une tolerance chez un sujet allergique a l'arachide
USD866321S1 (en) 2018-07-27 2019-11-12 Aimmune Therapeutics, Inc. Box of boxes for dispensing medicine
EP3829632A4 (en) 2018-07-27 2022-05-04 Société des Produits Nestlé S.A. SYSTEMS AND METHODS FOR DELIVERING UNIT DOSES OF ORAL IMMUNOTHERAPY
USD866322S1 (en) 2018-07-27 2019-11-12 Aimmune Therapeutics, Inc. Medicine folio
USD866320S1 (en) 2018-07-27 2019-11-12 Aimmune Therapeutics, Inc. Box of boxes for dispensing medicine
US12433945B2 (en) * 2018-08-16 2025-10-07 Société des Produits Nestlé S.A. Peanut oral immunotherapy with maintenance dose
AU2019401576A1 (en) 2018-12-17 2021-06-24 Société des Produits Nestlé S.A. Formulations for egg oral immunotherapy, methods of manufacture, and treatments for egg allergy
US12226448B2 (en) 2018-12-20 2025-02-18 Société des Produits Nestlé S.A. Peanut oral immunotherapy dosing schedule for missed doses
EP3942299A4 (en) 2019-03-22 2023-06-28 Société des Produits Nestlé S.A. Systemic allergic response risk assessment in peanut oral immunotherapy
WO2020237181A1 (en) 2019-05-23 2020-11-26 Aimmune Therapeutics, Inc. Methods of treating peanut allergy by oral immunotherapy with low-dose maintenance

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103596589A (zh) * 2011-03-17 2014-02-19 剑桥实业有限公司 花生过敏症的治疗
WO2019089978A1 (en) * 2017-11-02 2019-05-09 Aimmune Therapeutics, Inc. Methods of oral immunotherapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JEFFREY M. FACTOR等: "Effect of oral immunotherapy to peanut on food-specific quality of life", ANN ALLERGY ASTHMA IMMUNOL, vol. 109, no. 5, pages 348 - 352 *

Also Published As

Publication number Publication date
US20230090380A1 (en) 2023-03-23
AU2020276213A1 (en) 2021-10-28
EP3965815A1 (en) 2022-03-16
US20200368304A1 (en) 2020-11-26
US11229673B2 (en) 2022-01-25
JP2022532547A (ja) 2022-07-15
CA3137295A1 (en) 2020-11-19
WO2020231843A1 (en) 2020-11-19
JP7574222B2 (ja) 2024-10-28
EP3965815A4 (en) 2023-05-31

Similar Documents

Publication Publication Date Title
Wasserman et al. Real-world experience with peanut oral immunotherapy: lessons learned from 270 patients
CN113966229A (zh) 用于改善花生过敏患者的生活质量的方法
Mullins Anaphylaxis: risk factors for recurrence
Buchanan et al. Egg oral immunotherapy in nonanaphylactic children with egg allergy
JP7498661B2 (ja) 経口免疫療法の方法
Greiwe et al. AAAAI work group report: trends in oral food challenge practices among allergists in the United States
JP7536035B2 (ja) ピーナツに対する経口免疫療法における全身性アレルギー応答リスク評価
Shapiro et al. Feasibility and acceptability of CD‐ROM‐based cognitive‐behavioural treatment for binge‐eating disorder
Nourbakhsh et al. Treatment of fatigue with methylphenidate, modafinil and amantadine in multiple sclerosis (TRIUMPHANT-MS): Study design for a pragmatic, randomized, double-blind, crossover clinical trial
Kochs et al. The use of complementary and alternative medicine in patients with multiple sclerosis: a longitudinal study
WO2020237181A1 (en) Methods of treating peanut allergy by oral immunotherapy with low-dose maintenance
Alqadi et al. Effects of fasting during Ramadan on seizure control and quality of life in patients with epilepsy
Mbizvo et al. Levetiracetam add‐on for drug‐resistant focal epilepsy
Yahia et al. Oral immunotherapy for children with a high-threshold peanut allergy
Saetre et al. Antiepileptic drugs and quality of life in the elderly: results from a randomized double-blind trial of carbamazepine and lamotrigine in patients with onset of epilepsy in old age
Huber et al. Attentional and emotional mechanisms of pain processing and their related factors: a structural equations approach
HK40067853A (en) Methods for improving the quality of life of a patient with a peanut allergy
Kwong et al. Urticaria and angioedema: pathophysiology, diagnosis, and treatment
Beavis et al. A prospective multi-centre open label study of the use of levetiracetam as add-on treatment in patients with epilepsy and intellectual disabilities
You et al. Clinical experience with sesame oral immunotherapy and a quality-of-life assessment
Carpay et al. Parent-reported subjective complaints in children using antiepileptic drugs: what do they mean?
Kim et al. Effects of the immunoglobulin/histamine complex on panic disorder concurrent with chronic spontaneous urticaria: a case report
El-Baz et al. Child abuse experiences in adolescents with externalizing disorders.
Lanza et al. Effect of psycho-pedagogical preparation before gastric bypass
Probst et al. Quality of reporting health behaviors for multiple sclerosis (QuoRH‐MS): A scoping review to inform intervention planning and improve consistency of reporting

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
TA01 Transfer of patent application right

Effective date of registration: 20220309

Address after: Vevey

Applicant after: Societe des Produits Nestle S.A.

Address before: California, USA

Applicant before: Aimu therapy Co.

TA01 Transfer of patent application right
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40067853

Country of ref document: HK